Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytoSorbentsCTSO +10.38%31 Debt-to-Equity is -39.18 as of Jun. 2026. GuruFocus rates CTSO with a GF Score™ of 31/100 and a GF Value™ of $0.86 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 702 Medical Devices & Instruments companies, CytoSorbents ranks worse than 142450% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CytoSorbents's Debt-to-Equity or its related term are showing as below:
CTSO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -39.18 Med: 0.75 Max: 13.34
Current: -39.18
During the past 13 years, the highest Debt-to-Equity Ratio of CytoSorbents was 13.34. The lowest was -39.18. And the median was 0.75.
CTSO's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.22
vs CTSO: -39.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CytoSorbents Debt-to-Equity Related Terms
CytoSorbents Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CytoSorbents's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTSO vs GTHP, LFWD, PETV: Debt-to-Equity Comparison
For the Medical Devices subindustry, CytoSorbents's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoSorbents Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CytoSorbents's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CytoSorbents (CTSO) has a Debt-to-Equity of -39.18 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CytoSorbents and its competitors. According to the industry distribution chart, CytoSorbents ranks #999999 out of 702 companies in the Medical Devices & Instruments industry.
Is CytoSorbents' Debt-to-Equity too high?
CytoSorbents' current Debt-to-Equity is -39.18. Based on the distribution chart, CytoSorbents ranks #999999 out of 702 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, CytoSorbents has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Debt-to-Equity compare to GTHP and LFWD?
According to the Medical Devices & Instruments industry distribution chart, CytoSorbents ranks #999999 out of 702 companies for Debt-to-Equity. This places CytoSorbents in the lower half of its industry. The industry median Debt-to-Equity is 0.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.22, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CytoSorbents and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoSorbents's current Debt-to-Equity is -39.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
Based on GuruFocus' analysis, CytoSorbents (CTSO) is currently considered Possible Value Trap. The stock's GF Value™ is $0.86, compared to a current price of $0.40 — trading 53.5% below its estimated fair value. The current Debt-to-Equity is -39.18. CytoSorbents' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CytoSorbents (CTSO), the current Debt-to-Equity is -39.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytoSorbents (CTSO) Overvalued in 2026?
Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued.
The current stock price of $0.40 is trading 53.5% below its estimated GF Value™ of $0.86.
GuruFocus considers CytoSorbents to be Possible Value Trap.
Key valuation signals for CTSO:
Debt-to-Equity: -39.18
GF Value™: $0.86 vs. price of $0.40 (53.5% below fair value)
No single metric tells the full story. See the CTSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
31GF Score
Get the complete analysis for CTSO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTSO has been successfully added to your 
